Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call revealed strong financial performance, with a 30% YoY revenue increase and improved gross margins. Despite a net loss, the reduction from the previous year and improved cash flow are positive indicators. Raised revenue and gross margin guidance, along with optimistic future strategies and market expansion plans, further support a positive sentiment. However, the absence of operational updates and unclear management responses in the Q&A slightly temper the outlook, leading to a positive but not strong positive rating.
Key Financial Performance
Revenue Revenue for Q4 2025 was $252 million, representing a 30% increase year-over-year. This growth was driven by strong demand for our oncology and women's health products.
Gross Margin Gross margin improved to 55% in Q4 2025, up from 50% in the same period last year. The improvement was due to operational efficiencies and higher test volumes.
Operating Expenses Operating expenses were $180 million in Q4 2025, a 20% increase year-over-year. The increase was primarily due to investments in R&D and expansion of the sales team.
Net Loss Net loss for Q4 2025 was $50 million, compared to a net loss of $70 million in Q4 2024. The reduction in net loss was attributed to higher revenues and improved gross margins.
Cash Flow Cash flow from operations was negative $10 million in Q4 2025, an improvement from negative $30 million in Q4 2024. This was due to better working capital management and increased revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company is making forward-looking statements regarding future events and anticipated future performance, which inherently carry risks if assumptions do not materialize as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Operational and Financial Outlook: The company will discuss anticipated future performance, including operational and financial projections.
Market Size and Partnerships: Expectations regarding market size and partnerships will be addressed.
Clinical Studies and Expected Results: Future clinical studies and their expected outcomes will be discussed.
Opportunities and Strategies: The company will outline future opportunities and strategies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bank Research
Brophy Chief
Catherine Ramsey
Co Research
Diagnostics Alexey
Director Solomon
Division Leonard
Division Markowitz
Division PM
Division Puneet
Division Westenberg
EST Natera
Equities Research
Evercore ISI
ISI Institutional
Institutional Equities
Investment Bank
LLC Casey
Leonard UBS
Markowitz Evercore
Officer Catherine
Officer Fesko
Officer Steve
PM EST
Piper Sandler
Ramsey Baird
Research Division
Sandler Co
Solomon Moshkevich
Steve Chapman
UBS Investment
Westenberg Piper
NTRA Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Positive2-26
The company's earnings call revealed strong financial performance, with a 30% YoY revenue increase and improved gross margins. Despite a net loss, the reduction from the previous year and improved cash flow are positive indicators. Raised revenue and gross margin guidance, along with optimistic future strategies and market expansion plans, further support a positive sentiment. However, the absence of operational updates and unclear management responses in the Q&A slightly temper the outlook, leading to a positive but not strong positive rating.
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Natera, Inc. (NTRA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Neutral11-20
Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-19
NTRA Slides
NTRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
